A review and evaluation of study design considerations for omega-3 fatty acid supplementation trials in physically trained participants
Key Findings
Anthony et al. systematically reviewed the trials that supplemented long-chain omega-3 PUFA (EPA and/or DHA) in physically trained participants, assessing study quality and design rather than pooling effects. Forty-six studies (n=46) met inclusion, most randomised controlled designs.
Cochrane risk-of-bias judgments were predominantly "some concerns" (randomised controlled), "high risk" (randomised crossover) or "moderate risk" (non-randomised). On a custom five-point quality scale for omega-3 trial design, no study satisfied all recommendations.
The authors conclude that the disparate range of doses, durations and designs is likely why the evidence for omega-3 as an ergogenic aid remains inconclusive, and that future trials need a clear hypothesis and the omega-3-specific design considerations already established in cardiovascular research, to arrive at evidence-based dose, duration and composition recommendations.
Key Issues (from the abstract)
Wide range of doses, durations and designs across trials → no clear recommendation possible yet.
Risk of bias: "some concerns" / "high" / "moderate" depending on design; none low across the board.
Custom 5-point omega-3 design checklist: 0 of 46 studies met all points.
Design lessons should be borrowed from cardiovascular-disease omega-3 research (where they are already detailed).
The abstract reports no dose range in grams, no Omega-3 Index values, no duration range and no responder criteria; figures for these in earlier versions of this entry were not from the paper.
Practical Application
Across 46 omega-3 supplementation trials in physically trained adults, not one met all five design recommendations for such trials, and bias judgments were mostly "some concerns" or worse — so there is currently no evidence-based dose, duration or EPA:DHA composition for athletes, and the inconclusive performance literature reflects the designs as much as the supplement (systematic review of trial quality, Anthony 2024).
Read any single omega-3 trial's headline through this lens: dose, duration, baseline omega-3 status and composition varied so much between studies that results are not comparable.
What this means for an athlete deciding whether to supplement: the safety/recovery case (REF-188) can stand on its own, but a specific performance promise cannot — and "the studies disagree" is a design problem, not proof of no effect.
Not from this paper; the base's own practice: an athlete who tries omega-3 measures the Omega-3 Index before and after a multi-week trial and keeps dose and product constant, so that the personal test has the controls the published trials lacked. No numeric target or dose is stated here, because this review shows none is yet evidence-based.
Design Strengths & Limitations
Strengths: Systematic search (SCOPUS, PubMed, Web of Science); design-appropriate Cochrane risk-of-bias tools; custom quality scale specific to omega-3 trial design.
Limitations
From the design as the abstract reports it: a systematic review of trial quality in physically trained adults (46 studies); it judges design and risk of bias and pools no effect estimates.
Limitations: Methodological review — evaluates how trials were built, not whether omega-3 works; no meta-analysis; the five-point scale is the authors' own instrument.
How this entry was checked and changed
Content correction 2026-09-27
Table of ranges (dose 0.5-5 g/day, baseline Omega-3 Index 2-12%, duration 3-24 weeks, EPA:DHA 1:2-5:1) deleted: none of these figures is in the abstract.
"Standardization recommendations" with 2400 mg EPA + 1200 mg DHA, ≥8 weeks, 2-3× dose arms and 4/8/12-16-week outcome timing deleted: invented, not the paper's recommendations.
"Responder / non-responder phenotype" (VO2max <65 or >70, >15 or <10 h/week, Omega-3 Index <6% / >8%, sushi 3×/week) deleted: not from the paper.
Added the abstract's actual findings: 46 studies, mostly RCTs, risk-of-bias pattern, 0/46 meeting all five design recommendations. Type corrected to systematic review of study design; Tier "4-5 elite" -> mixed→2-3; Sport cycling -> general.
Cross-references to duplicate stubs repointed to their canonical entries (REF-162->REF-306); the stubs were emptied on 2026-09-27.
Cross-reference descriptions checked against the cited entries' current content; wrong years, wrong entries and claims the cited entry does not make were corrected.
2026-09-28: added Limitations from the abstract (Europe PMC/PubMed PMID 36620998).